Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.076
Neutral
RSI(14)
42.453
Neutral
STOCH(KDJ)(9,3,3)
18.973
Sell
ATR(14)
0.229
Low Volatility
CCI(14)
-147.967
Sell
Williams %R
89.189
Oversold
TRIX(12,20)
0.145
Sell
StochRSI(14)
0.000
Oversold
Search
X4 Pharmaceuticals Inc
XFORAdd to Watchlist
3.940USD
-0.060-1.50%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
371.62MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of X4 Pharmaceuticals Inc
Currency: USD Updated: 2026-05-15Key Insights
X4 Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 102 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 11.67.In the medium term, the stock price is expected to trend up.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
X4 Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
X4 Pharmaceuticals Inc Highlights
StrengthsRisks
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Growing
The company is in a growing phase, with the latest annual income totaling USD 35.11M.
Fairly Valued
The company’s latest PE is -1.20, at a medium 3-year percentile range.
Held by Steven Cohen
Star Investor Steven Cohen holds 808.15K shares of this stock.
Analyst Rating
Based on
3
analysts
Strong Buy
Current Rating
11.667
Target Price
+191.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of X4 Pharmaceuticals Inc is 5.25, ranking 153 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 2.71M, representing a year-over-year decrease of 90.60%, while its net profit experienced a year-over-year decrease of 7277.66%.
Score
Financials
6.30
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.58
Operational Efficiency
2.84
Growth Potential
2.45
Shareholder Returns
7.08
X4 Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of X4 Pharmaceuticals Inc is 7.05, ranking 98 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -1.20, which is -16423.31% below the recent high of 195.65 and -26280.72% above the recent low of -316.20.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 102/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of X4 Pharmaceuticals Inc is 9.33, ranking 2 out of 155 in the Pharmaceuticals industry. The average price target is 7.50, with a high of 13.00 and a low of 4.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Strong Buy
Current Rating
11.667
Target Price
+191.67%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
X4 Pharmaceuticals Inc
XFOR
3
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of X4 Pharmaceuticals Inc is 4.11, ranking 146 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 4.45 and the support level at 3.65, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
4.202
Sell
MA10
4.252
Sell
MA20
4.219
Sell
MA50
4.146
Sell
MA100
3.922
Buy
MA200
3.625
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of X4 Pharmaceuticals Inc is 3.00, ranking 94 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 9.67%, representing a quarter-over-quarter decrease of 89.43%. The largest institutional shareholder is Steven Cohen, holding a total of 808.15K shares, representing 0.86% of shares outstanding, with 128.91% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of X4 Pharmaceuticals Inc is 2.79, ranking 117 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.32. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. X4 Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
0.32
VaR
+9.22%
240-Day Maximum Drawdown
+66.98%
240-Day Volatility
+110.15%
Return
Best Daily Return
60 days
+18.82%
120 days
+18.82%
5 years
+81.69%
Worst Daily Return
60 days
-10.39%
120 days
-13.46%
5 years
-53.17%
Sharpe Ratio
60 days
+1.78
120 days
+0.58
5 years
-0.09
Risk Assessment
Maximum Drawdown
240 days
+66.98%
3 years
+97.66%
5 years
+99.22%
Return-to-Drawdown Ratio
240 days
+0.05
3 years
-0.32
5 years
-0.20
Skewness
240 days
+4.48
3 years
+1.98
5 years
+1.55
Volatility
Realised Volatility
240 days
+110.15%
5 years
+118.04%
Standardised True Range
240 days
+7.53%
5 years
+83.90%
Downside Risk-Adjusted Return
120 days
+111.98%
240 days
+111.98%
Maximum Daily Upside Volatility
60 days
+62.64%
Maximum Daily Downside Volatility
60 days
+43.33%
Liquidity
Average Turnover Rate
60 days
+5.73%
120 days
+6.66%
5 years
--
Turnover Deviation
20 days
-94.25%
60 days
-92.84%
120 days
-91.67%
Peer Comparison
Pharmaceuticals
X4 Pharmaceuticals Inc
XFOR
5.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
